Edition:
United Kingdom

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

82.02USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$82.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,339
52-wk High
$100.99
52-wk Low
$13.11

Select another date:

Wed, Dec 6 2017

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69‍​

* Madrigal Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

BRIEF-Madrigal Pharma announces $35 million private placement offering

* Madrigal pharmaceuticals announces $35 million private placement offering

Select another date: